{"filings":[{"id":96404,"accession_number":"0001867096-26-000027","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q1 revenue up 43% to $82M; Recorlev nearly doubles to $50M; raises FY guidance to $380-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.","Recorlev net revenue $49.8M, up 95% driven by patient demand; Gvoke flat at $20.8M; Keveyis $11.9M, up 4%.","Adjusted EBITDA $15.1M, improvement of $10.7M YoY; gross margin improved to 87% from 85%.","Raises FY2026 total revenue guidance; tightens range to $380-390M (>30% growth at midpoint).","Plans Phase 3 initiation of XP-8121 later in 2026; commercial team expansion completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":83127000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96403,"accession_number":"0001867096-26-000020","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeffrey Sherman to retire from Xeris Biopharma board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeffrey Sherman notified Board of his retirement and will not stand for reelection at the 2026 Annual Meeting.","Sherman will continue serving on Compensation and Nominating/Governance committees until his term expires.","Board reduced from eight to seven directors effective after Sherman's term ends at the 2026 Annual Meeting.","Sherman stated his retirement is not due to any disagreement with the company or its management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110284,"accession_number":"0001867096-26-000012","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.","Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).","FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.","Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.","Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110283,"accession_number":"0001867096-26-000010","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris Biopharma sues Torrent, Somerset over Recorlev patent infringement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed Hatch-Waxman lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over ANDA for generic Recorlev.","Lawsuit alleges infringement of four Orange Book patents expiring March 2040 (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940, 12,377,096).","Seeks injunction to block generic competition until patent expiry in March 2040.","Recorlev also benefits from Orphan Drug Exclusivity through December 2028.","CEO John P. Shannon cites confidence in IP and intention to vigorously defend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110282,"accession_number":"0001867096-26-000004","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.","Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.","Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.","Positive Adjusted EBITDA delivered in each quarter of 2025.","Full 2025 results and 2026 outlook to be released March 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":291845000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126862,"accession_number":"0001867096-25-000161","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.","Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.","CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.","Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.","XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126861,"accession_number":"0001867096-25-000156","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).","Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).","Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.","FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.","CEO cites record quarter driven by increased patient demand across all three products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":206038000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143659,"accession_number":"0001867096-25-000130","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).","Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.","Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.","Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.","Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":131658000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161873,"accession_number":"0001867096-25-000104","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xeris Biopharma reports Annual Meeting voting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class I directors elected: Bormann (57.1M for), Brady (76.5M for), Kong (75.9M for).","Ratification of Ernst & Young as auditor for FY2025: 110.1M for, 0.7M against.","Advisory say-on-pay compensation vote passed: 72.2M for, 5.6M against, 0.9M abstain.","All proposals passed with required votes; no material changes to board or auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161872,"accession_number":"0001867096-25-000100","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris unveils long-range strategy; targets ~$750M revenue by 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.","Expects total revenue of ~$750M by 2030, led by Recorlev growth.","Anticipates Recorlev annual net revenue of ~$1B in 2035; XP-8121 peak net revenue $1-3B.","Cites Recorlev revenue acceleration as inflection point to self-fund near- and long-term growth.","Hosts first Analyst and Investor Day on June 3, 2025, in New York City."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161871,"accession_number":"0001867096-25-000085","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.","Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).","Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.","FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.","Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":60119000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179932,"accession_number":"0001867096-25-000054","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xeris appoints James Brady to board, directors Ricki Fairley and John Schmid depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ricki Fairley resigned effective March 28, 2025; no disagreement with company.","John Schmid will not stand for reelection at 2025 Annual Meeting; board to reduce to eight members.","James Brady appointed as Class I director, will chair Audit Committee if reelected.","Brady brings 30+ years at AstraZeneca, most recently CFO of MedImmune; also serves on Verona Pharma (VRNA) board.","Brady received initial equity grant of 100,000 RSUs under non-employee director compensation plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179931,"accession_number":"0001867096-25-000034","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)","Recorlev Q4 revenue $22.6M (+131% YoY); full-year $64.3M (+118% YoY)","Q4 net loss $5.1M (($0.03)/share); Adjusted EBITDA $8.3M; cash $71.6M","FY2025 revenue guidance $255M-$275M; expects positive Adjusted EBITDA going forward"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179930,"accession_number":"0001867096-25-000031","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xeris appoints Dr. Anh Nguyen as CMO; Ken Johnson retiring April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Anh Nguyen named Chief Medical Officer effective Feb 24, 2025.","Ken Johnson, SVP Global Dev & Medical Affairs, to retire April 1, 2025.","Nguyen will lead Medical, Regulatory, Preclinical/Clinical Dev, Pharmacovigilance.","Nguyen previously served as program medical lead for Gvoke NDA/MAA at Xeris."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179929,"accession_number":"0001867096-25-000017","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).","Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.","Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.","Year-end cash, equivalents, and short-term investments expected to be over $71M.","Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":203070000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196730,"accession_number":"0001867096-24-000183","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).","Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).","FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.","Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.","12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":142971000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213027,"accession_number":"0001867096-24-000157","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.","Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.","Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.","John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.","Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":88703000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213026,"accession_number":"0001867096-24-000137","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xeris Biopharma promotes Kevin McCulloch to President and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.","McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.","He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.","Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.","McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213025,"accession_number":"0001867096-24-000124","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.","Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.","Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.","Year-end 2024 cash guidance reaffirmed at $55M to $75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232145,"accession_number":"0001867096-24-000102","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xeris stockholders approve all proposals; ESPP shares increased by 6.64M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).","Ernst & Young ratified as auditor for FY2024 (99.5M for).","Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.","ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.","Broker non-votes on director election and advisory items: ~36.2M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232144,"accession_number":"0001867096-24-000062","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).","Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).","Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.","Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.","Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":40638000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250411,"accession_number":"0001867096-24-000024","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","2.02","2.03","8.01","9.01"],"status":"ready","headline":"Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.","Net loss in Q4 $13.4M ($0.10 loss per share); year-end cash $72.5M.","FY2024 guidance: total net revenue $170M-$200M; year-end cash $55M-$75M.","Refinanced existing $150M Hayfin loan with new $200M term loan; additional $15.2M available to redeem 2025 notes.","New loan bears 6.95% + SOFR (floor 2%) interest; maturity March 2029; reduces borrowing cost by 2.05%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}